Scholarlink

<p>Cardiac damage staging is a validated predictor of outcomes in tricuspid aortic valve aortic stenosis (TAV-AS), but its role in bicuspid aortic valve aortic stenosis (BAV-AS) remains unclear. We compared baseline characteristics, cardiac damage stages, and clinical outcomes between BAV-AS and TAV-AS patients. We analyzed 3365 patients with severe aortic stenosis (AS) from the CURRENT AS Registry-2, including 222 with BAV-AS and 3143 with TAV-AS. Cardiac damage stages were classified based on index echocardiographic findings. The primary outcome was a composite of death or heart failure hospitalization. BAV-AS patients were significantly younger and had fewer cardiovascular comorbidities than TAV-AS patients. Despite greater AS severity, BAV-AS patients more often presented with less advanced cardiac damage (stage 0–1: 53% versus 29%, <i>P</i> &lt; 0.001). Among patients aged &lt; 75 years, early-stage cardiac damage was more prevalent in BAV-AS, whereas TAV-AS patients aged &lt; 75 years showed higher rates of advanced cardiac damage. The cumulative 3-year incidence of the primary outcome was significantly lower in BAV-AS than in TAV-AS (9.9% versus 38.4%, <i>P</i> &lt; 0.001). Adjusted analysis confirmed that BAV-AS remained significantly associated with better outcome (hazard ratio: 0.53, 95% confidence interval: 0.33–0.86, <i>P</i> = 0.01). BAV-AS patients exhibited more favorable baseline profiles, less advanced cardiac damage, and better prognosis despite greater AS severity, highlighting the prognostic value of cardiac damage staging irrespective of valve morphology.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiac damage stages and prognosis in patients with bicuspid versus tricuspid aortic valve: insights from the CURRENT AS Registry-2

  • 期刊论文

  • 发表日期：

    2026年3月3日

查看全文
  • Wataru Saitoh,
  • Tomohiko Taniguchi,
  • Yasuaki Takeji,
  • Takeshi Morimoto,
  • Shinichi Shirai,
  • Kenji Ando,
  • Ryosuke Murai,
  • Kohei Osakada,
  • Kotaro Takahashi,
  • Tomohisa Tada,
  • Koichiro Murata,
  • Yuki Obayashi,
  • Masashi Amano,
  • Takeshi Kitai,
  • Chisato Izumi,
  • Shojiro Tatsushima,
  • Norio Kanamori,
  • Makoto Miyake,
  • Hiroyuki Nakayama,
  • Masayasu Izuhara,
  • Kazuya Nagao,
  • Kenji Nakatsuma,
  • Moriaki Inoko,
  • Eisaku Nakane,
  • Hiroki Fukuda,
  • Yuhei Yamaji,
  • Mariko Kitano,
  • Hideyuki Hayashi,
  • Masahiro Kimura,
  • Mitsuru Ishii,
  • Shunsuke Usami,
  • Fumiko Nakazeki,
  • Manabu Shirotani,
  • Yasutaka Inuzuka,
  • Koh Ono,
  • Kenji Minatoya,
  • Takeshi Kimura

摘要

Cardiac damage staging is a validated predictor of outcomes in tricuspid aortic valve aortic stenosis (TAV-AS), but its role in bicuspid aortic valve aortic stenosis (BAV-AS) remains unclear. We compared baseline characteristics, cardiac damage stages, and clinical outcomes between BAV-AS and TAV-AS patients. We analyzed 3365 patients with severe aortic stenosis (AS) from the CURRENT AS Registry-2, including 222 with BAV-AS and 3143 with TAV-AS. Cardiac damage stages were classified based on index echocardiographic findings. The primary outcome was a composite of death or heart failure hospitalization. BAV-AS patients were significantly younger and had fewer cardiovascular comorbidities than TAV-AS patients. Despite greater AS severity, BAV-AS patients more often presented with less advanced cardiac damage (stage 0–1: 53% versus 29%, P < 0.001). Among patients aged < 75 years, early-stage cardiac damage was more prevalent in BAV-AS, whereas TAV-AS patients aged < 75 years showed higher rates of advanced cardiac damage. The cumulative 3-year incidence of the primary outcome was significantly lower in BAV-AS than in TAV-AS (9.9% versus 38.4%, P < 0.001). Adjusted analysis confirmed that BAV-AS remained significantly associated with better outcome (hazard ratio: 0.53, 95% confidence interval: 0.33–0.86, P = 0.01). BAV-AS patients exhibited more favorable baseline profiles, less advanced cardiac damage, and better prognosis despite greater AS severity, highlighting the prognostic value of cardiac damage staging irrespective of valve morphology.

Graphical Abstract